IMPROVE-IT: Scenarios for understanding the results
Prof. Chris Packard (Glasgow) reviews the potential implications of new LDL-c lowering clinical trial outcomes for ezetimibe and new therapeutic options such as PCSK9 inhibitors
View
Slides • 8-9-2014
LDL-c lowering by statins & cholesterol absorption inhibitors: Do we need anything new?
Presentation by prof. Chris Packard during the PACE 2014 SNAPSHOT session on August 30, 2014 in BarcelonaThe information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: